Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Depreciation & Amortization (CF) (2016 - 2025)

Dexcom (DXCM) has disclosed Depreciation & Amortization (CF) for 16 consecutive years, with $65.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 12.8% to $65.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $251.8 million, a 15.66% increase, with the full-year FY2025 number at $251.8 million, up 15.66% from a year prior.
  • Depreciation & Amortization (CF) was $65.2 million for Q4 2025 at Dexcom, up from $63.6 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $65.2 million in Q4 2025 to a low of $20.9 million in Q1 2021.
  • A 5-year average of $45.7 million and a median of $45.9 million in 2023 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): soared 85.53% in 2022, then grew 0.23% in 2023.
  • Dexcom's Depreciation & Amortization (CF) stood at $32.1 million in 2021, then increased by 13.08% to $36.3 million in 2022, then skyrocketed by 44.63% to $52.5 million in 2023, then grew by 10.1% to $57.8 million in 2024, then increased by 12.8% to $65.2 million in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Depreciation & Amortization (CF) are $65.2 million (Q4 2025), $63.6 million (Q3 2025), and $63.0 million (Q2 2025).